Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics adds Robert J. Spiegel, M.D. to its board of directors

Neutral Impact 2 of 5 leadership Written later

Ernexa Therapeutics appointed Robert J. Spiegel, M.D. as a member of its board of directors, effective immediately, on the recommendation of the Nominating and Corporate Governance Committee. The filing says he will be compensated under the company's board compensation plan and reports no related-party transactions or family relationships with other directors or executives.

Key points

  • Board appointment approved September 14, 2026; effective immediately
  • Dr. Spiegel's compensation follows the Board of Directors Compensation Plan adopted effective August 15, 2026
  • Filing reports no reportable transactions with Dr. Spiegel under Item 404(a) of Regulation S-K

The filing

CompanyErnexa Therapeutics Inc. (ERNA)
Form8-K, current report
Filed with the SECSep 16, 2026, 4:50 PM ET
Accession number0001493152-26-042934

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.